Full Description
Type 2 diabetes is a major global health concern, and is predicted to affect between 10% to 25% of the world's population in the next 20 years. This epidemic is mostly attributed to ageing populations and unhealthy lifestyles. Thusly, understanding how the mind interacts with the body is essential in unlocking the psychological, biological, and sociocultural processes that increase the risk of type 2 diabetes and make it such a difficult condition to treat. Depression is a common co-morbid condition and when both conditions are present, this poses a significant challenge to patients, clinicians, and health care systems globally.
Depression and Type 2 Diabetes is a unique resource offering a fresh scientific approach to this frequent co-morbidity. Using the latest research and guidelines, this resource provides readers with a comprehensive overview of the subject at the different stages of human lifespan, from the uterine environment where the metabolic thermostat is first set, to growing old with diabetes.
Written and edited by international experts in diabetes and depression, Depression and Type 2 Diabetes reviews, critiques, and advances the latest research on the prevalent and complex relationship between depression and type 2 diabetes.
Contents
1: Stefan F. Bornstein, Andreas Birkenfeld, and Julio Licinio: Global burden of diabetes and depression
2: Khalida Ismail, Calum D. Moulton, Andrea Danese, and Brenda W. Penninx: A lifecourse approach to understanding the association between depression and type 2 diabetes
3: Henning Morawietz, Richard C. Siow, and Mohamad Musbah Almedawar: MicroRNAs as novel biomarkers in depression, diabetes and cardiovascular diseases
4: Carol Kan and Ma-Li Wong: Genetics
5: Calum D. Moulton and John Pickup: Innate immunity and inflammation in type 2 diabetes-associated depression
6: Allan H. Young and Mario F. Jurena: Hypothalamic-Pituitary-Adrenal (HPA) axis
7: Carla Petrella, Giuseppe Nistico, and Robert Nistico: Gut-brain axis: physiology
8: Norbert Hermanns, Marijke Bremmer, and Frank Snoek: Diabetes distress
9: Calum Moulton and Clive Ballard: The association between depression and cognitive impairment in type 2 diabetes
10: Frank Petrak and Bonnie Röhrig: Treatment of depression in type 2 diabetes
11: Andreas Barthel and Michael Bauer: Risks and benefits of psychotropics
12: Lidia Castagneto Gissey, James Casella Mariolo, Geltrude Mingrone, and Francesco Rubino: Metabolic surgery and depression
13: Calum Moulton: Novel pharmacological targets
14: Harold Lebovitz and Shlomo Ben Haim: Novel technologies
15: Christopher Garrett: Current and emerging psychological models
16: Eleanor M Scott and Gregory Potter: Targeting the circadian rhythm
17: Kirsty Winkley, Ebaa Al-Ozairi, and Boon How Chew: Cultural and global perspectives
18: Peter Schwarz and Patrick Timpel: National and international policy initiatives on multi-morbidity
